Atopic Dermatitis : A New Treatment Paradigm Using Pimecrolimus
March 2003 | Volume 2 | Issue 2 | Original Article | 131 | Copyright © March 2003
Jeffrey M. Weinberg, MD; James G. Bowerman, MD; Stuart M. Brown, MD; David Gerstein, MD; Kay S. Kane, MD; James Selevan, MD and Sat Virdee, MD
Abstract
Atopic dermatitis (AD), often called eczema, is a disease characterized by intense pruritus, erythema, dry skin,
and inflammation. Pimecrolimus is a novel steroid-free treatment for AD. Consistently positive results have
been found with pimecrolimus treatment in infants, children/adolescents, and adults. Its safety record is excellent,
and studies have found no clinically relevant drug-related systemic adverse events. In this article, we first
review atopic dermatitis and conventional treatment strategies. We then discuss various aspects of pimecrolimus,
including pharmacologic properties, toxicology, short- and long-term studies, and safety and adverse
events. Finally, we propose a new steroid-sparing treatment strategy for AD.